Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOXO-783 in PIK3CA-mutant advanced breast cancer and solid tumors
jRCT2031220276Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of LOXO-783 in breast cancer and Nonhematologic neoplasms (8 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of patients with dose-limiting toxicities and Number of patients with DLT-equivalent toxicities. Started Sep 2022; status: active, not recruiting.
02
Drugs
LOXO-783
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220276.